Consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 535,031	$ 494,366	$ 351,318
Cost of revenues	114,877	106,501	88,606
Gross profit	420,154	387,865	262,712
Operating costs and expenses:
Research, development and clinical studies	201,303	132,010	79,003
Sales and marketing	137,057	118,017	96,675
General and administrative	126,127	107,437	87,948
Total operating costs and expenses	464,487	357,464	263,626
Operating income (loss)	(44,333)	30,401	(914)
Financial expenses (income), net	7,742	12,299	7,910
Income (loss) before income taxes	(52,075)	18,102	(8,824)
Income tax	6,276	(1,706)	(1,594)
Net income (loss)	$ (58,351)	$ 19,808	$ (7,230)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.56)	$ 0.20	$ (0.07)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	103,433,274	100,930,866	97,237,549
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.56)	$ 0.18	$ (0.07)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	103,433,274	108,877,648	97,237,549